This opportunity is no longer accepting applications.
grant PAR-23-279

Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)

This grant aims to support research focused on understanding how incretin mimetics (drugs affecting hormones like GLP-1 and GIP-1) influence cancer risk, rather than their short-term effects like weight loss or diabetes. The goal is to attract knowledgeable scientists to explore the mechanisms by which these agents may increase the risk of certain cancers while decreasing the risk of others as…

The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientist…

Funding Source

Agency: National Institutes of Health
Sub-agency: National Cancer Institute
Program: SBIR

Dates

Opportunity Released: August 23, 2023
Open for Submission: August 23, 2023
Submission Deadline: January 7, 2027
Application Window Closes: January 7, 2027

Supporting links

Secure Grant Funding 10x Faster

Scout delivers AI-powered grant writing paired with experts that's faster, more affordable, and built to win.

Already have an account? Sign In

Trusted by 500+ Happy Customers

Get opportunities sent to your inbox

The latest grant news and insights from our experts.

Save this opportunity and explore more

Share Opportunity

Share this opportunity with others.
Anyone with this link can view the opportunity details.